title: [Burning sensation in oral cavity--burning mouth syndrome in everyday medical practice].
abstract: Burning mouth syndrome (BMS) refers to chronic orofacial pain, unaccompanied by mucosal lesions or other evident clinical signs. It is observed principally in middle-aged patients and postmenopausal women. BMS is characterized by an intense burning or stinging sensation, typically on the tongue or in other areas of the oral mucosa. It can be accompanied by other sensory disorders such as dry mouth or taste alterations. Probably of multifactorial origin, and often idiopathic, with a still unknown etiopathogenesis in which local, systemic and psychological factors are implicated. Currently there is no consensus on the diagnosis and classification of BMS. This study reviews the literature on this syndrome, with special reference to the etiological factors that may be involved and the clinical aspects they present. The diagnostic criteria that should be followed and the therapeutic management are discussed with reference to the most recent studies.
authors.affiliation: Pécsi Tudományegyetem, AOK, Fül-, orr-, gégészeti és Fej-, nyaksebészeti Klinika. i.gerlinger@freemail.hu
authors.forename: Imre
authors.initials: I
authors.lastname: Gerlinger
mesh_terms: D000081:Acetamides / Q000627:therapeutic use; D000588:Amines / Q000627:therapeutic use; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D002054:Burning Mouth Syndrome / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology / Q000523:psychology / Q000628:therapy; D002707:Chlordiazepoxide / Q000627:therapeutic use; D002998:Clonazepam / Q000627:therapeutic use; D015928:Cognitive Behavioral Therapy; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D005260:Female; D000077206:Gabapentin; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010292:Paresthesia / Q000150:complications / Q000175:diagnosis; D010523:Peripheral Nervous System Diseases / Q000150:complications / Q000175:diagnosis; D010591:Phantom Limb / Q000150:complications / Q000175:diagnosis; D010880:Piperidines / Q000627:therapeutic use; D011379:Prognosis; D011725:Pyridines / Q000627:therapeutic use; D012737:Sex Factors; D008063:Thioctic Acid / Q000627:therapeutic use; D014059:Tongue / Q000503:physiopathology; D014987:Xerostomia / Q000150:complications / Q000175:diagnosis; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
chemical_list: D000081:Acetamides; D000588:Amines; D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D000975:Antioxidants; D003509:Cyclohexanecarboxylic Acids; D006635:Histamine H2 Antagonists; D010880:Piperidines; D011725:Pyridines; C076948:lafutidine; D005680:gamma-Aminobutyric Acid; D002998:Clonazepam; D000077206:Gabapentin; D002707:Chlordiazepoxide; D008063:Thioctic Acid